CDT Short Interest Climbs 70.8% as Biotech Cash Burn Erases 99.9% of Peak Value

Biotech investors tracking CDT Equity are witnessing a classic penny-stock death spiral: a once-high-flying clinical-stage name has shed 99.9% of its value, and short sellers are now piling on with a 70.8% increase in short interest. The company’s Phase I assets for autoimmune conditions and male fertility, which once briefly captured market enthusiasm, are now valued by the market at barely above zero, raising serious questions about funding and path forward.

In a stark display of bearish sentiment sweeping through the micro-cap life sciences sector, both Co-Diagnostics, Inc. (NASDAQ: CODX) and CDT Equity Inc. (NASDAQ: CDT) experienced dramatic surges in short interest during May 2026. According to data from May 29, CODX short interest ballooned 79.9% from the mid-May reporting period to 349,389 shares, now representing a full 10% of the company’s outstanding stock sold short. CDT saw similar—though smaller in absolute terms—increases, with short interest jumping 70.8% to 53,538 shares, or 1.2% of its total shares. The near-simultaneous spikes in bearish positioning highlight the extreme risk profile these companies present, with both trading at penny-stock levels and facing existential questions about their ability to survive.

“

With a market capitalization of $14.11 million and a stock price hovering at $3.83—down 91.8% from its 12-month high of $46.50—the firm’s equity is essentially a call option on a turnaround that appears increasingly distant.

The numbers behind these short-interest moves are stark. Co-Diagnostics, a diagnostics technology company, reported quarterly revenue of just $150,000 against a net loss that produced a staggering negative net margin of 6,760.63% and a negative return on equity exceeding 164%. With a market capitalization of $14.11 million and a stock price hovering at $3.83—down 91.8% from its 12-month high of $46.50—the firm’s equity is essentially a call option on a turnaround that appears increasingly distant. Analysts remain mixed but notably bearish: Weiss Ratings downgraded the stock to 'sell (e+)', while Wall Street Zen assigned a 'sell' rating. Despite a consensus analyst price target of $67.50, the enormous gap between that target and the current price suggests either outdated models or a near-total disconnect from market reality.

CDT Equity, whose operating entity is clinical-stage biopharmaceutical company Conduit Pharmaceuticals, paints an even more extreme picture. The stock has collapsed from a 12-month high of $610.00 to just $0.71, losing 99.9% of its value and reducing its market cap to a mere $3.45 million. The company’s pipeline, which includes Phase I-completed assets targeting autoimmune diseases and idiopathic male infertility, has evidently not convinced investors of any viable path to commercialization. With a P/E ratio of zero and an average analyst rating of 'sell' (Weiss Ratings reaffirmed its 'sell (e+)' stance in March), short sellers are piling on, betting that the equity will go to zero.

A peculiar detail in both cases is the extremely low short-interest ratio—essentially 0.0 days for both stocks, given their high average daily trading volumes. For CODX, average daily volume exceeds 34 million shares, meaning the entire short position could theoretically be covered in a single trading session without moving the price significantly. This creates a double-edged dynamic: while the high volume suggests liquidity and a potential floor, it also signals rampant speculative trading that could fuel a short squeeze if any positive catalyst emerges. However, the sheer magnitude of the fundamental deterioration—negative margins, tiny revenues, and dwindling cash reserves—makes a sustained rally unlikely without a transformative event.